Divi's Laboratories
Other · 2 quarters tracked · source-linked performance and management context.
Latest revenue
₹2,604 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
0
Across 3 tracked commitments: 0 delivered, 3 missed.
Call date
2026-01-23
latest available source date
Signal trajectory
2 actual quartersCurrent read
0/100
Across 3 tracked commitments: 0 delivered, 3 missed.
Latest source read
What changed this quarter?
Divi's Laboratories reported Q3 FY26 PAT of ₹583 crore, broadly flat YoY, impacted by a one-time exceptional charge of ₹74 crore due to labor code changes. Revenue mix improved with custom synthesis at 57% (9M), driving gross margin expansion as material consumption fell to 36.3% of sales (vs 39.8% YoY). Management highlighted strong volume traction in generics despite pricing pressure, and multiple CS projects progressing toward commercialization over the next year, with three dedicated facilities expected to start commercial volumes by Q3-Q4 CY2027. The peptide segment continues to advance, with a dedicated commercial building for large-scale SPS reactors now in validation. Backward integration at Unit 3 is supporting margins and freeing up GMP capacity. Key risk: pricing pressure in generics may persist longer than expected, limiting value growth.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹2,604 Cr
Source date
2026-01-23
Across the record
Quarter history.
History modules